Efficacy of antihypertensive treatment: Which endpoints should be considered?

Nephrology Dialysis Transplantation

Volumn 20, Issue 11, 2005, Pages 2301-2303

  Mancia, Giuseppe ^a   Grassi, Guido ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Antihypertensive treatment; Cardiovascular mortality

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; FATALITY; HEART PROTECTION; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PATIENT ATTITUDE; PATIENT SELECTION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; TIME;

ADULT; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; HUMANS; HYPERTENSION; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 27644483110     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi092     Document Type: Editorial

References (12)

1. 3 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. J Hypertens 2003; 21: 1011-1053
2. Swales JD. Clinical trials: What more is needed? A critical view. J Hypertens 1996; 14 [Suppl]: S83-S86
3. Mancia G. Role of large clinical trials in providing information on antihypertensive treatment. Importance and limitations. J Hypertens 2005; in press.
4. Wilcox RG, Hampton JR, Banks DC et al. Trial of early nifedipine in acute myocardial infarction: The Trent study. Br Med J 1986; 293: 1204-1208
5. Medical Research Council Working Party. MRC Trial of treatment of mild hypertension: Principal results. Medical Research Council. Br Med J 1985; 291: 97-104
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to Angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997
7. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242: 2562-2571
8. de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927
9. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202
10. Mathew J, Sleight P, Lonn E et al. for the Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104: 1615-1621
11. Devereux RB, Wachtell K, Gerdts E et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292: 2350-2356
12. Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: A meta-analysis. Am J Hypertens 2003; 16: 895-899